SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium/glucose cotransporter 2 (SGLT2) inhibito...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Diabetes
Prif Awduron: Tuttle, Katherine R., Brosius, Frank C., Cavender, Matthew A., Fioretto, Paola, Fowler, Kevin J., Heerspink, Hiddo J.L., Manley, Tom, McGuire, Darren K., Molitch, Mark E., Mottl, Amy K., Perreault, Leigh, Rosas, Sylvia E., Rossing, Peter, Sola, Laura, Vallon, Volker, Wanner, Christoph, Perkovic, Vlado
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Diabetes Association 2021
Pynciau:
Perspectives in Diabetes
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8162454/
https://ncbi.nlm.nih.gov/pubmed/33106255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dbi20-0040
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg